FDA: Frequently Asked Questions — Developing Potential Cellular and Gene Therapy Products

1. Operational/Timeline Changes (highest practical impact)

• ESG tracking number lead time: Draft allowed issuance no earlier than 4 weeks before the target receipt date. Final extends this to 8 weeks. Sponsors can (and should) request tracking numbers earlier.
• INTERACT meeting PS number: Draft required sponsors to actively request a PS number via RIB. Final states no pre-assigned PS number is required — one is automatically assigned upon submission of the INTERACT request, removing an administrative step.
• Pre-BLA meeting length: Shortened from 90 minutes (draft) to 60 minutes (final). Sponsors should plan a tighter agenda.
• Pre-BLA briefing package question limit: Reduced from up to 15 questions/sub-questions (draft) to up to 10 (final). Sponsors must prioritize questions more aggressively.
• Form 1571 field for "Commercial IND": Corrected from Field 6B (draft) to Field 7B (final).

2. New or Revised CMC/Quality Expectations

• Release test qualification trigger changed: Draft tied qualification/AC/CGMP compliance for release tests to *initiating Phase 2 or 3 studies*. Final ties it to initiating a pivotal study intended to provide primary evidence of effectiveness — a more precise (and potentially later or earlier, depending on trial design) trigger than a fixed phase number.
• Interim vs. commercial acceptance criteria: Final adds explicit language that interim AC are acceptable for Phase 2/3, but proposed commercial AC should be in place at BLA submission (this replaces the draft's vaguer statement that final AC aren't expected until "the end of clinical development").
• Analytical method fitness-for-purpose: Final clarifies this means "phase-appropriate" and adds that safety assays (e.g., microbial testing) should demonstrate suitability under actual conditions of use and absence of interference — not just adequate performance.
• Pharmacy/clinical-site handling instructions: New requirement that instructions for receiving, handling, preparing, and administering product at the clinical site (Pharmacy Manual, IFU, IB) be provided in Module 5, hyperlinked to the quality section in Module 2.
• CQA submissions: Final adds that sponsors should include assessments of quality-relevant attributes, CQA determination rationale, and specification justification based on available data.
• Scaled-down models: Final expands acceptable uses to include viral or impurity clearance studies, not just process design/characterization.
• New CMC reference: Final cites a brand-new guidance, *"Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a BLA"* (May 2026) — not available when the draft was issued.
• Stability: Final adds a pointer to the CMC GT INDs Guidance for shipping stability, in-use stability, and device compatibility topics.
• Manufacturing changes/comparability: Final specifically flags that meeting requests to discuss comparability are especially important when changes occur later in development.
• CGMP applicability: Final emphasizes CGMP compliance applies "at all stages of clinical investigation" (not just at BLA), reinforcing that this isn't a late-stage-only concern.

3. Nonclinical/Pharm-Tox Changes

• GLP flexibility (new): Final explicitly allows non-GLP studies with QA oversight following GLP practices when technical limitations prevent full GLP compliance, provided QA is independent of study-conducting personnel. This wasn't addressed in the draft.
• SEND datasets (new requirement): Final adds that for nonclinical studies initiated after March 15, 2023, standardized SEND-format datasets are required.
• Comparability of clinical vs. nonclinical product: Final adds an expectation that nonclinical studies use the final clinical product (or a documented comparison to the product used) — not addressed in the draft.
• NAMs (New Approach Methodologies): Final explicitly endorses NAMs in multiple places (species selection, alternative test methods, dose extrapolation) where the draft only referenced the 3Rs generally. This includes a new provision that dose-level extrapolation may rely on in vitro/NAM data when in vivo studies aren't technically feasible.
• LNP/mRNA-specific content (new): Final adds substantial new material specific to lipid nanoparticle (LNP)-based gene therapy products:
• Comparability of analogous animal products should address lipid identity/quality, final lipid formulation, cargo (e.g., mRNA), and manufacturing process (Q25).
• Biodistribution methods should include LC-MS/MS for LNP products and measurement of cargo RNA, alongside qPCR/ddPCR for viral vectors (Q30).
• This is the clearest sign that FDA broadened the guidance's scope beyond viral-vector/cell-based products to address the growing volume of LNP/mRNA-based CGT submissions.
• Tumorigenicity language softened slightly: "Usually necessary" (draft) → "generally recommended" (final) for pluripotent stem cell-derived products.
• Related product data: Final clarifies "related product" for read-across purposes means "products of the same or similar class."

4. Meeting Process Changes

• INTERACT meeting purpose statement: Final adds framing language that INTERACT is intended for "novel products and development programs that present unique challenges in early development."
• INTERACT/pre-IND readiness threshold: Draft said INTERACT is appropriate before sponsors "designed and conducted definitive toxicology studies"; final broadens this to definitive nonclinical studies.
• Guidance renumbering: SOPP 8101.1 (draft) → SOPP 8101 (final).
• Rolling review: Final clarifies that sponsors should obtain preliminary agreement at the pre-BLA meeting or earlier (e.g., end-of-Phase-2 meeting) — this wasn't explicit in the draft.

5. Regulatory/Effectiveness Standard Updates

• Substantial evidence guidance reference updated: The draft cited the long-standing December 2019 draft guidance on demonstrating substantial evidence of effectiveness. The final guidance now cites an updated version issued June 2026 — sponsors relying on this citation should pull the current version, not the 2019 draft.
• Wording softened from "FDA has interpreted the substantial evidence requirement as generally requiring two adequate and well-controlled clinical investigations" to "substantial evidence may be satisfied by two adequate and well-controlled clinical investigations" — a subtle but real shift toward flexibility in framing (not a change in the two-trial default, but less rigid phrasing).

6. New References Added in the Final Guidance

Sponsors should note the following new source documents cited only in the final version (not available/finalized at draft stage):

• Ref 9 (final numbering): *Study Data Technical Conformance Guide*, updated June 2026
• Ref 39: *Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a BLA*, Guidance for Industry, May 2026
• Ref 40: *Expedited Program for Serious Conditions – Accelerated Approval of Drugs and Biologics*, Draft Guidance, December 2024
• Ref 35: *Demonstrating Substantial Evidence of Effectiveness...*, now dated June 2026 (was a 2019 draft)

7. Minor Items Worth Flagging

• The final document contains a couple of unresolved Word cross-reference errors ("Error! Bookmark not defined.") near the Tumorigenicity/Proof-of-Concept section headers — a formatting artifact, not substantive, but worth knowing if citing this guidance from the original PDF.
• Table of contents in the final version lists Q36 as "gene therapies" while the body text still says "CGT therapies" — an inconsistency, likely a drafting leftover.
• Section III was retitled from "Interacting with FDA" to "Submissions and FDA Review".
• Preclinical Assessment CGT Guidance date corrected from "April 2008" (draft, incorrect) to "November 2013" (final, correct).

The differences are generated by AI models and can contain mistakes. Please double-check the content.